Can Depo (medroxyprogesterone acetate) injections be given to patients with hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Depo Injections Be Given to Patients with Hypertension?

Yes, Depo-Provera (medroxyprogesterone acetate) can be safely given to patients with hypertension, as it does not raise blood pressure and may actually lower it. 1

Blood Pressure Effects of Depo-Provera

Depot medroxyprogesterone acetate (DMPA) has no appreciable effects on blood pressure, distinguishing it from combined hormonal contraceptives that contain estrogen. 2

  • In a prospective study of 24 women receiving 150 mg DMPA injections, mean blood pressure actually decreased from 124.1/79.4 to 115.6/73.2 mm Hg over three months of treatment. 3
  • DMPA provides a simple, effective alternative for women who cannot use combined oral contraceptive pills due to hypertension. 2
  • Progestogen-only methods like DMPA show no significant association with high blood pressure development during 2-3 years of follow-up. 4

Contraindications Related to Blood Pressure

The only absolute contraindication involving blood pressure is uncontrolled severe hypertension (BP >160/110 mm Hg) when considering combined hormonal contraceptives, not DMPA. 1

  • Combined hormonal contraceptive pills and transdermal patches are absolutely contraindicated in individuals with uncontrolled hypertension (BP >160/110 mm Hg). 1
  • Caution should be exercised with combined hormonal contraceptives in individuals with controlled hypertension (BP ≥140/90 mm Hg), but this does not apply to progestogen-only DMPA. 1
  • DMPA is specifically recommended for women at risk of coronary heart disease due to presence of risk factors like hypertension. 4

Clinical Advantages for Hypertensive Patients

DMPA offers specific benefits for hypertensive patients that combined hormonal methods cannot provide. 2, 5

  • DMPA has no thrombosis risk, unlike combined oral contraceptives, making it safer for women with cardiovascular risk factors. 2
  • The method is independent of daily adherence and does not require the strict timing needed for progestogen-only pills, which is advantageous for women with irregular lifestyles or multiple medications. 2
  • DMPA has a typical use failure rate of 0.3%, making it one of the most effective reversible contraceptive methods available. 6

Administration Guidelines for Hypertensive Patients

Standard DMPA administration protocols apply to hypertensive patients without modification. 7

  • Administer 150 mg intramuscularly or 104 mg subcutaneously every 13 weeks. 7, 6
  • The injection can be given up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection. 7
  • Screen for new contraindications at each visit, including history of stroke, myocardial infarction, pulmonary embolism, or deep vein thrombosis. 7

Important Counseling Points

All patients receiving DMPA, including those with hypertension, require specific counseling about non-blood pressure related effects. 6

  • Counsel about menstrual irregularities, which occur in nearly all patients initially, as pre-injection counseling significantly improves continuation rates. 6
  • Reinforce daily calcium and vitamin D intake, regular weight-bearing exercise, and avoidance of smoking and alcohol due to bone mineral density concerns. 7, 6
  • Monitor weight changes at follow-up visits, as weight gain is a common concern with significant individual variability. 7, 6
  • Emphasize that DMPA provides no protection against sexually transmitted infections, so condom use should be encouraged. 7

Common Pitfall to Avoid

Do not withhold DMPA from hypertensive patients based on concerns about blood pressure elevation, as this is not supported by evidence. 4, 3, 2

  • The concern about blood pressure elevation applies to combined hormonal contraceptives containing estrogen, not to progestogen-only DMPA. 1
  • Do not limit DMPA use to 2 years based solely on bone density concerns, as the benefits of pregnancy prevention outweigh the risks. 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Depo Provera. Position paper on clinical use, effectiveness and side effects.

The British journal of family planning, 1999

Research

The effect of medroxyprogesterone acetate on blood pressure.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1978

Guideline

Depo-Provera Contraceptive Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Approach to Administering Depo Shots

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.